BridgeBio Pharma, Inc. Business Finance Contracts & Agreements
31 Contracts & Agreements
- Indenture Agreements (2 contracts)
- Loan Agreements (8)
- Purchase Agreements (5)
- Registration Rights Agreements (4)
- Stock Agreements (8)
- Underwriting Agreements (4)
- Underwriting Agreement, dated as of March 5, 2024, by and among the Company, J.P. Morgan Securities LLC, Cantor Fitzgerald & Co. and Mizuho Securities USA LLC, as representatives... (Filed With SEC on March 6, 2024)
- Registration Rights Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc. and the purchasers party thereto (Filed With SEC on September 25, 2023)
- Securities Purchase Agreement, dated September 25, 2023, by and among BridgeBio Pharma, Inc. and the purchasers party thereto (Filed With SEC on September 25, 2023)
- Form of Non-Qualified Stock Option Agreement under BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan (2023 Form) (Filed With SEC on August 3, 2023)
- Form of Restricted Stock Award Agreement under BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan (2023 Form) (Filed With SEC on August 3, 2023)
- Form of Restricted Stock Unit Award Agreement under BridgeBio Pharma, Inc. Amended and Restated 2019 Inducement Equity Plan (2023 Form) (Filed With SEC on August 3, 2023)
- Underwriting Agreement, dated as of March 7, 2023, by and among the Company, Goldman Sachs & Co. LLC, Evercore Group L.L.C. and Morgan Stanley & Co. LLC, as representatives of the... (Filed With SEC on March 9, 2023)
- Loan and Security Agreement, among U.S. Bank National Association in its capacity as Administrative Agent and Collateral Agent, the Lenders party thereto, the Registrant, and... (Filed With SEC on February 25, 2022)
- Amended and Restated Employee Stock Purchase Plan (Filed With SEC on November 4, 2021)
- Amended and Restated Employee Stock Purchase Plan (Filed With SEC on May 6, 2021)
- Sixth Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of April 13, 2021 (Filed With SEC on May 6, 2021)
- Fifth Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of January 25, 2021 (Filed With SEC on February 25, 2021)
- Third Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of March 2, 2020 (Filed With SEC on February 25, 2021)
- Underwriting Agreement, dated as of February 11, 2021, by and among the Company, the Selling Stockholder and Goldman Sachs & Co. LLC, as the representative of the several... (Filed With SEC on February 17, 2021)
- Indenture, dated as of January 28, 2021, by and between BridgeBio Pharma, Inc. and U.S. Bank National Association, as Trustee (Filed With SEC on January 29, 2021)
- Purchase Agreement, dated January 25, 2021, by and among BridgeBio Pharma, Inc. and J.P. Morgan Securities LLC and Mizuho Securities USA LLC, as representatives of the several... (Filed With SEC on January 26, 2021)
- Amended and Restated 2019 Employee Stock Purchase Plan, effective December 12, 2019 (Filed With SEC on November 5, 2020)
- Indenture, dated as of March 9, 2020, by and between BridgeBio Pharma, Inc. and U.S. Bank National Association, as Trustee (Filed With SEC on March 10, 2020)
- Purchase Agreement, dated March 4, 2020, by and among BridgeBio Pharma, Inc. and J.P. Morgan Securities LLC and BofA Securities, Inc., as representatives of the several Initial... (Filed With SEC on March 6, 2020)
- Loan and Security Agreement dated November 13, 2019 between Eidos Therapeutics, Inc., a partially owned subsidiary of Registrant, as borrower, Silicon Valley Bank and Hercules... (Filed With SEC on November 19, 2019)
- Registration Rights Agreement (Filed With SEC on July 3, 2019)
- 2019 Employee Stock Purchase Plan (Filed With SEC on June 24, 2019)
- Form of Registration Rights Agreement, among the Registrant and certain of its shareholders, to be in effect immediately prior to completion of this offering (Filed With SEC on June 24, 2019)
- Specimen Common Stock Certificate (Filed With SEC on June 24, 2019)
- Form of Underwriting Agreement (Filed With SEC on June 24, 2019)
- Second Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital Inc., dated as of May 17, 2019 (Filed With SEC on May 24, 2019)
- Asset Purchase Agreement, among Phoenix Tissue Repair, Inc., Shire Human Genetic Therapies, Inc., and Lotus Tissue Repair, Inc., dated as of July 21, 2017 (Filed With SEC on May 24, 2019)
- Asset Purchase Agreement, among BridgeBio Pharma LLC, Origin Biosciences, Inc., and Alexion Pharma Holding Unlimited Company, dated as of June 7, 2018 (Filed With SEC on May 24, 2019)
- First Amendment to the Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of December 28, 2018 (Filed With SEC on May 24, 2019)
- Loan and Security Agreement, between BridgeBio Pharma LLC and Hercules Capital, Inc., dated as of June 19, 2018 (Filed With SEC on May 24, 2019)
- Form of Registration Rights Agreement, among the Registrant and certain of its shareholders, to be in effect immediately prior to completion of this offering (Filed With SEC on May 24, 2019)
